{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:44:36Z","timestamp":1758969876167,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K06910","JP21H02844","JP22K07538","JP22H04921","JP22H04923"],"award-info":[{"award-number":["JP20K06910","JP21H02844","JP22K07538","JP22H04921","JP22H04923"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21wm0425018","JP21wm0425019"],"award-info":[{"award-number":["JP21wm0425018","JP21wm0425019"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00415-023-11754-7","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T10:02:17Z","timestamp":1683540137000},"page":"4544-4548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["RNA interference in late-stage hereditary transthyretin amyloidosis: a clinicopathological study"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8890-2743","authenticated-orcid":false,"given":"Goichi","family":"Beck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yonenobu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Ikenaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fusako","family":"Sera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Morii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneaki","family":"Yoshinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"11754_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","volume":"29","author":"Y Ando","year":"2022","unstructured":"Ando Y, Adams D, Benson MD et al (2022) Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid 29:143\u2013155","journal-title":"Amyloid"},{"key":"11754_CR2","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL (2012) Transthyretin (TTR) cardiac amyloidosis. Circulation 126:1286\u20131300","journal-title":"Circulation"},{"key":"11754_CR3","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, da Silva AM et al (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802\u20132814","journal-title":"J Neurol"},{"key":"11754_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321","journal-title":"N Engl J Med"},{"key":"11754_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","volume":"20","author":"D Adams","year":"2021","unstructured":"Adams D, Polydefkis M, Gonz\u00e1lez-Duarte A et al (2021) Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol 20:49\u201359","journal-title":"Lancet Neurol"},{"key":"11754_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS et al (2023) Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 30:1\u20139","journal-title":"Amyloid"},{"key":"11754_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331","journal-title":"N Engl J Med"},{"key":"11754_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","volume":"40","author":"G Holmgren","year":"1991","unstructured":"Holmgren G, Steen L, Ekstedt J et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40:242\u2013246","journal-title":"Clin Genet"},{"key":"11754_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0022-510X(87)90265-6","volume":"79","author":"M Nakazato","year":"1987","unstructured":"Nakazato M, Kangawa K, Kurihara T, Matsukura S, Matsuo H (1987) Variant transthyretin in cerebrospinal fluid in familial amyloidotic polyneuropathy. J Neurol Sci 79:111\u2013116","journal-title":"J Neurol Sci"},{"key":"11754_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho T, Adams D, Silva A et al (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369:819\u2013829","journal-title":"N Engl J Med"},{"key":"11754_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","volume":"10","author":"OB Suhr","year":"2015","unstructured":"Suhr OB, Coelho T, Buades J et al (2015) Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 10:109","journal-title":"Orphanet J Rare Dis"},{"key":"11754_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A et al (2019) Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139:431\u2013443","journal-title":"Circulation"},{"key":"11754_CR13","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/jnc.15162","volume":"156","author":"T Murakami","year":"2021","unstructured":"Murakami T, Yokoyama T, Mizuguchi M et al (2021) A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy. J Neurochem 156:957\u2013966","journal-title":"J Neurochem"},{"key":"11754_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3109\/13506129909007341","volume":"6","author":"N Tachibana","year":"1999","unstructured":"Tachibana N, Tokuda T, Yoshida K et al (1999) Usefulness of MALDI\/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid 6:282\u2013288","journal-title":"Amyloid"},{"key":"11754_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s42466-021-00155-8","volume":"3","author":"MF Dohrn","year":"2021","unstructured":"Dohrn MF, Medina J, Olaciregui Dague KR, Hund E (2021) Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis. Neurol Res Pract 3:57","journal-title":"Neurol Res Pract"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11754-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11754-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11754-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T12:04:18Z","timestamp":1691755458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11754-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["11754"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11754-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"13 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was carried out in accordance with the principles of the Declaration of Helsinki, and was approved by the Ethics Committee of Osaka University Hospital (No. 20043).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the family of the patient described in this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}